— Technology Description:
Researchers at Washington University in St. Louis have developed a biomarker screening assay to predict which patients receiving CAR T cell therapy will experience neurotoxicity. Patients can be screened well in advance of receiving the T cell therapy with a simple serum as…
— Technology Description
A team of researchers, led by Richard Hotchkiss at Washington University in St. Louis, have developed a version of the ELISpot assay to determine if COVID-19 patients are in a hyper-inflammatory or immunosuppressed state. The results of this assay, which can be performed wit…
— Technology Description
Researchers in Prof. Marco Colonna’s laboratory have identified a receptor-ligand interaction that could be harnessed to activate the innate immune system to treat cancer or enhance the response to vaccines for infectious disease. Specifically, platelet-derived growth f…
— Technology Description:
Researchers in the lab of Emil Unanue at Washington University have discovered a panel of peptides responsible for autoimmune activation in Type 1 diabetes and potentially capable of diagnosing T1D at an early stage. These peptide fragments of insulin are found circulating …
— Plasminogen activator inhibitor-1 (PAI-1) has been identified as a specific biomarker that is significantly elevated in patients with inflammatory bowel disease (IBD) and is correlated with disease severity. It could be used to both diagnose the disease (including ulcerative colitis and colonic Croh…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
